Click here to view the DVT Part II webcast online.
This program will be available beginning September 10 at 12:30 p.m. EST
Improving DVT Prevention, Detection and Treatment in High-Risk Specialties Strategies to improve DVT prophylaxis, early identification, treatment and post discharge follow-up in OB/GYN and neurology patients
Release Date: September 10, 2008
Termination Date: September 9, 2009
Media Used: Satellite, Webcast, DVD & VHS
Time to Complete the Activity: 1 Hour 30 Minutes
National experts will discuss barriers and provocative issues in DVT management, and will share mission-critical strategies to address this major cause of morbidity and mortality for these patient groups accounting for approximately half of hospital admissions. Part II will focus on the OB/GYN and neurology patients.
ACTIVITY OBJECTIVES
Upon completion of this activity, participants should be able to:
1. Describe the impact of DVT/PE in the five specialties for patients in the US and to appreciate the world wide impact of
VTE
2. Identify relevant DVT/PE recommendations and guidelines, including those of the ACCP, CMS and relevant
professional societies
3. Define high risk groups for venous thromboembolism in hospitalized patients
4. Identify clinical factors that contribute to thromboembolic risk in the orthopedic, oncology, cardiology, neurology,
and OB/GYN patient
5. Describe recommended strategies for prevention of venous thromboembolism for various risk groups
6. Discuss therapeutic approaches for thromboprophylaxis, including the risks and benefits associated with
anticoagulants, low-molecular-weight heparins, and mechanical methods
7. Identify patients who qualify for extended-duration prophylaxis
8. Appropriately document DVT/PE patient care (including Risk assessment, prophylaxis, and patient discharge
instructions)
Medical Moderator
William A. Brock, MD, MS, FACS
Vice President, Chief Quality Officer
Presbyterian Hospital of Plano
Plano, Texas
FACULTY
Neurology
Joseph A. Caprini, MD, MS, FACS
Professor, Department of Surgery
Feinberg School of Medicine
Northwestern University
Chicago, IL
OB/GYN
Thomas C. Krivak, MD
Assistant Professor, Department of Obstetrics,
Gynecology and Reproductive Sciences
Division of Gynecologic Oncology
University of Pittsburgh Medical Center
UPMC Cancer Center at Magee-Womens Hospital
Pittsburgh, Pennsylvania
|
September 10, 2008
Eastern: 12:30 – 2 p.m.
Central: 11:30 a.m. – 1 p.m.
Mountain: 10:30 a.m. – 12 p.m.
Pacific: 9:30 – 11 a.m.
|
September 18, 2008
(Re-Air)
Eastern: 3:30 – 5 p.m.
Central: 2:30 – 4 p.m.
Mountain: 1:30 – 3 p.m.
Pacific: 12:30 – 2 p.m.
|
September 24, 2008
(Re-Air)
Eastern: 8:30 – 10 a.m.
Central: 7:30– 9 a.m.
Mountain: 6:30– 8 a.m.
Pacific: 5:30 – 7 a.m.
|
ACCREDITATION
PHYSICIAN
The Research and Education Institute for Texas Health Resources is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Research and Education Institute for Texas Health Resources designates this educational activity for a maximum of 1.5 (for each session) AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NURSING
Presbyterina Hospital of Plano, Education Department, has approved this program for 1.5 contact hours. This program has been approved by the American Assoication of Critical-Care Nurses (AACN).
If your organization is interested in participating in an outcomes research study around DVT please contact Professional Education at 866-865-5448.
The opinions expressed in this program are those of the speaker and do not necessarily reflect the opinions or recommendations of the speaker's affiliated institutions, the publisher, The Research and Education Institute for Texas Health Resources (the accreditor), GlaxoSmithKline or sanofi-aventis U.S. (the commercial supporter), or CRM Healthcare. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.
|
